Therapy Effect of the Stable Gastric Pentadecapeptide BPC 157 on Acute Pancreatitis as Vascular Failure-Induced Severe Peripheral and Central Syndrome in Rats.
acute pancreatitis
gastric pentadecapeptide BPC 157
rats
severe peripheral and central syndrome
vascular failure
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
01 Jun 2022
01 Jun 2022
Historique:
received:
16
04
2022
revised:
24
05
2022
accepted:
27
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross and microscopy presentation, decreased amylase level). Additionally, we revealed the therapy's effect on the acute pancreatitis as vascular failure and multiorgan failure, both peripherally and centrally following "occlusion-like" syndrome, major intoxication (alcohol, lithium), maintained severe intra-abdominal hypertension, and myocardial infarction, or occlusion syndrome, and major vessel occlusion. The application-sacrifice periods were ligation times of 0-30 min, 0-5 h, 0-24 h (cured periods, early regimen) and 4.30 h-5 h, 5 h-24 h (cured periods, delayed regimen). Otherwise, bile duct-ligated rats commonly presented intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, gross brain swelling, hemorrhage and lesions, heart dysfunction, lung lesions, liver and kidney failure, gastrointestinal lesions, and severe arterial and venous thrombosis, peripherally and centrally. Unless antagonized with the key effect of BPC 157 regimens, reversal of the inferior caval and superior mesenteric vein congestion and reversal of the failed azygos vein activated azygos vein-recruited direct delivery to rescue the inferior-superior caval vein pathway; these were all antecedent to acute pancreatitis major lesions (i.e., acinar, fat necrosis, hemorrhage). These lesions appeared in the later period, but were markedly attenuated/eliminated (i.e., hemorrhage) in BPC 157-treated rats. To summarize, while the innate vicious cycle may be peripheral (bile duct ligation), or central (rapidly developed brain disturbances), or peripheral and central, BPC 157 resolved acute pancreatitis and its adjacent syndrome.
Identifiants
pubmed: 35740321
pii: biomedicines10061299
doi: 10.3390/biomedicines10061299
pmc: PMC9220115
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : University of Zagreb
ID : 099
Références
Oxid Med Cell Longev. 2019 Dec 30;2019:9084643
pubmed: 31976029
Neurosci Bull. 2019 Feb;35(1):167-170
pubmed: 30116973
Vascul Pharmacol. 2018 Jul;106:54-66
pubmed: 29510201
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):3-4
pubmed: 33203968
Front Pharmacol. 2021 Dec 13;12:718147
pubmed: 34966273
Curr Pharm Des. 2013;19(1):76-83
pubmed: 22950504
Gut Liver. 2020 Mar 15;14(2):153-167
pubmed: 31158953
Curr Pharm Des. 2018;24(18):1972-1989
pubmed: 29998800
J Physiol Paris. 2001 Jan-Dec;95(1-6):289-93
pubmed: 11595452
Eur J Pharmacol. 2019 Oct 15;861:172593
pubmed: 31401154
World J Gastroenterol. 2018 Dec 28;24(48):5462-5476
pubmed: 30622376
J Appl Physiol (1985). 2011 Mar;110(3):774-80
pubmed: 21030672
Eur J Pharmacol. 2016 Dec 15;793:56-65
pubmed: 27815173
Thromb Res. 2012 May;129(5):652-9
pubmed: 21840572
Biomedicines. 2021 Jul 15;9(7):
pubmed: 34356886
J Orthop Surg Res. 2019 Jul 2;14(1):199
pubmed: 31266512
Eur J Pharmacol. 1997 Jul 30;332(1):23-33
pubmed: 9298922
Drug Des Devel Ther. 2015 Apr 30;9:2485-99
pubmed: 25995620
World J Gastrointest Pathophysiol. 2020 Mar 13;11(1):1-19
pubmed: 32226643
Dig Dis Sci. 1992 Sep;37(9):1426-33
pubmed: 1380425
Biomedicines. 2021 Oct 20;9(11):
pubmed: 34829735
J Physiol Pharmacol. 2011 Oct;62(5):527-34
pubmed: 22204800
Regul Pept. 2013 Feb 10;181:50-66
pubmed: 23327997
Surgery. 1997 Aug;122(2):288-94
pubmed: 9288134
Am J Physiol Gastrointest Liver Physiol. 2020 Nov 1;319(5):G573-G583
pubmed: 32877220
Biomedicines. 2021 Jun 28;9(7):
pubmed: 34203464
Curr Pharm Des. 2018;24(18):1990-2001
pubmed: 29879879
World J Gastrointest Pharmacol Ther. 2020 Nov 8;11(5):93-109
pubmed: 33251034
Biomedicines. 2022 Jan 26;10(2):
pubmed: 35203478
Biomedicines. 2021 Dec 31;10(1):
pubmed: 35052769
Biomedicines. 2021 Jul 08;9(7):
pubmed: 34356860
J Physiol Paris. 2001 Jan-Dec;95(1-6):303-8
pubmed: 11595454
Emerg Med Int. 2020 May 27;2020:6805354
pubmed: 32566305
J Physiol Pharmacol. 2021 Dec;72(6):
pubmed: 35485358
Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16603-16612
pubmed: 31350349
Biomedicines. 2021 Sep 23;9(10):
pubmed: 34680419
Sci Rep. 2020 Oct 13;10(1):17078
pubmed: 33051481
J Crit Care. 2011 Apr;26(2):225.e11-8
pubmed: 21185146
Curr Pharm Des. 2014;20(7):1126-35
pubmed: 23755725
Brain Behav. 2020 Aug;10(8):e01726
pubmed: 32558293
World Neurosurg. 2014 Jul-Aug;82(1-2):169-74
pubmed: 23182733
Med Hypotheses. 2021 Nov 9;158:110736
pubmed: 34798584
PLoS One. 2016 Sep 14;11(9):e0162590
pubmed: 27627764
World J Hepatol. 2020 May 27;12(5):184-206
pubmed: 32547687
Life Sci. 2011 Mar 14;88(11-12):535-42
pubmed: 21295044
J Physiol Pharmacol. 2010 Apr;61(2):241-50
pubmed: 20436226
Biomedicines. 2021 Aug 17;9(8):
pubmed: 34440233
Front Pharmacol. 2021 Jun 29;12:627533
pubmed: 34267654
Molecules. 2014 Nov 19;19(11):19066-77
pubmed: 25415472
Inflammopharmacology. 2017 Apr;25(2):255-264
pubmed: 28255738
Eur J Pharmacol. 2019 Mar 15;847:130-142
pubmed: 30690000
World J Gastroenterol. 2022 Jan 7;28(1):23-46
pubmed: 35125818
J Pharmacol Sci. 2004 May;95(1):19-26
pubmed: 15153646
J Mol Med (Berl). 2017 Mar;95(3):323-333
pubmed: 27847966
Curr Pharm Des. 2018;24(18):1947-1956
pubmed: 29898649
J Physiol Paris. 1997 May-Oct;91(3-5):139-49
pubmed: 9403788
Gastroenterology. 1985 Jan;88(1 Pt 2):228-36
pubmed: 3871087
Life Sci. 1993;53(18):PL291-6
pubmed: 7901724
World Neurosurg. 2014 Jul-Aug;82(1-2):50-3
pubmed: 23920298
J Surg Res. 2002 Aug;106(2):335-41
pubmed: 12175989
Arch Surg. 1970 Oct;101(4):478-83
pubmed: 5457245
PLoS One. 2015 Apr 21;10(4):e0123454
pubmed: 25897838
Biomedicines. 2021 Oct 27;9(11):
pubmed: 34829776
Dig Dis Sci. 1996 Jul;41(7):1518-26
pubmed: 8689934
J Physiol Pharmacol. 2009 Dec;60 Suppl 7:107-14
pubmed: 20388953
J Physiol Sci. 2018 Sep;68(5):617-628
pubmed: 28929393
World J Gastroenterol. 2017 Dec 28;23(48):8465-8488
pubmed: 29358856
Gastroenterology. 1979 Oct;77(4 Pt 1):761-7
pubmed: 38173
Eur J Pharmacol. 2011 Sep 30;667(1-3):322-9
pubmed: 21645505
Regul Pept. 2009 Aug 7;156(1-3):83-9
pubmed: 19465062
Regul Toxicol Pharmacol. 2020 Jul;114:104665
pubmed: 32334036
World J Gastroenterol. 2004 Nov 15;10(22):3336-8
pubmed: 15484312
Neurosurgery. 2005 Sep;57(3):573-80; discussion 573-80
pubmed: 16145538
Biomedicines. 2021 May 26;9(6):
pubmed: 34073625
Stroke. 2005 Apr;36(4):841-6
pubmed: 15731475
Inflammopharmacology. 2017 May 17;:
pubmed: 28516373
Neural Regen Res. 2022 Mar;17(3):482-487
pubmed: 34380875
J Physiol Paris. 2001 Jan-Dec;95(1-6):315-24
pubmed: 11595456
World J Gastroenterol. 2017 Aug 7;23(29):5304-5312
pubmed: 28839430
World J Gastroenterol. 2018 Dec 21;24(47):5366-5378
pubmed: 30598581
Lab Invest. 1989 May;60(5):677-91
pubmed: 2469859
Curr Pharm Des. 2020;26(25):2971-2981
pubmed: 32445447
Life Sci. 2017 Oct 1;186:66-79
pubmed: 28797793
Curr Issues Mol Biol. 2022 Apr 27;44(5):1901-1927
pubmed: 35678659